FDA Approves Second-Line Ramucirumab in AFP-Elevated HCC
May 10, 2019 - The FDA has approved ramucirumab monotherapy for patients with hepatocellular carcinoma (HCC) who have an alpha fetoprotein (AFP) of ≥400 ng/ML and have been previously treated with sorafenib). The approval was based on findings from the international, ...Leggi tutto